Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Lepu Medical, a Medical Device Company, Raises $224 Million by Listing on Swiss Exchange

publication date: Sep 16, 2022

Beijing Lepu Medical Technology will raise $224 million by listing its Global Depositary Receipts on the SWX Swiss Exchange. The company makes medical devices, APIs, in-vitro diagnostics, biomarkers and surgical equipment. Lepu will use part of the proceeds for strategic investments, including building overseas R&D centers, production bases and business expansion centers. Lepu Medical made its debut on the Shenzhen GEM market in 2009. Several years ago, the company spun out its oncology drug development operations to Lepu Biopharma, which completed a $116 million Hong Kong IPO earlier this year. More details....

Stock Symbols: (SHA: 300003) (HK: 2157)

Share this with colleagues: